Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
40
EVGGF Quote, Financials, Valuation and Earnings
Last price:
$69.25
Seasonality move
:
10.66%
Day range:
$86.80 - $87.48
52-week range:
$71.50 - $114.60
Dividend yield:
3.24%
P/E ratio:
13.64x
P/S ratio:
8.25x
P/B ratio:
4.33x
Volume:
16
Avg. volume:
2.8K
1-year change:
-22.38%
Market cap:
$17.9B
Revenue:
$2.2B
EPS (TTM):
$6.41
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Evolution AB has -- downside to fair value with a price target of -- per share.
EVGGF vs. S&P 500
-
Over the past 5 trading days, Evolution AB has overperformed the S&P 500 by 2.38% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Evolution AB does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Evolution AB has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Evolution AB reported revenues of $569.1M.
Earnings Growth
-
Evolution AB has grown year-over-year earnings for 39 quarters straight. In the most recent quarter Evolution AB reported earnings per share of $1.95.
Enterprise value:
17.1B
EV / Invested capital:
--
Price / LTM sales:
8.25x
EV / EBIT:
12.43x
EV / Revenue:
7.64x
PEG ratio (5yr expected):
0.68x
EV / Free cash flow:
13.54x
Price / Operating cash flow:
14.61x
Enterprise value / EBITDA:
11.18x
Gross Profit (TTM):
--
Return On Assets:
24.72%
Net Income Margin (TTM):
60.27%
Return On Equity:
32.1%
Return On Invested Capital:
32.1%
Operating Margin:
61.11%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.5B | $1.9B | $2.2B | $511.9M | $569.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $954.7M | $1.2B | $1.4B | $325.9M | $347.7M | |
| EBITDA | $1.1B | $1.4B | $1.5B | $362.9M | $387.5M | |
| Diluted EPS | $4.08 | $5.35 | $6.41 | $1.42 | $1.95 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $614M | $916.4M | $1.2B | $1.9B | $2.1B | |
| Total Assets | $3.9B | $4.4B | $4.7B | $5.5B | $5.6B | |
| Current Liabilities | $452.9M | $419.1M | $456.7M | $620.5M | $1.1B | |
| Total Liabilities | $544.8M | $806.3M | $974.9M | $1.1B | $1.4B | |
| Total Equity | $3.4B | $3.6B | $3.7B | $4.4B | $4.1B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $925.4M | $1.3B | $1.4B | $335.1M | $339.7M | |
| Cash From Investing | -$391.9M | -$150.9M | -$268.4M | -$30.9M | -$36.9M | |
| Cash From Financing | -$415.7M | -$622M | -$1.3B | -$118.6M | -$150.1M | |
| Free Cash Flow | $823.1M | $1.2B | $1.3B | $302.7M | $303M | |
EVGGF
Sector
Market Cap
$17.9B
$401M
Price % of 52-Week High
76.33%
66.47%
Dividend Yield
3.24%
0%
Shareholder Yield
8.24%
3.88%
1-Year Price Total Return
-22.38%
-17.67%
Beta (5-Year)
1.211
0.832
Dividend yield:
3.24%
Annualized payout:
$2.84
Payout ratio:
44.99%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$85.35
200-day SMA
Sell
Level
$88.02
Bollinger Bands (100)
Buy
Level
74.98 - 83.66
Chaikin Money Flow
Buy
Level
245.4K
20-day SMA
Buy
Level
$80.42
Relative Strength Index (RSI14)
Buy
Level
66.40
ADX Line
Buy
Level
23.3
Williams %R
Sell
Level
-9.0939
50-day SMA
Buy
Level
$79.09
MACD (12, 26)
Buy
Level
2.47
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
482.2K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.6264)
Buy
CA Score
(Annual)
Level (2.226)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-4.5378)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Evolution AB is a B2B provider of live and slots casino systems. The Company develops, produces, markets and licenses fully integrated online casino systems to gaming operators. The company provides business-to-business solutions, which it develops and produces for gaming operators. Evolution's primary product, Live Casino, allows a human dealer to run a real-time casino table, which is then streamed to digital devices. Players can then place bets on desktops, smartphones, and tablets and communicate with the dealer through Evolution's software. The company's services are licensed to casino operators. The company generates the vast majority of its revenue across continental Europe.
Stock Forecast FAQ
In the current month, EVGGF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EVGGF average analyst price target in the past 3 months is --.
-
Where Will Evolution AB Stock Be In 1 Year?
According to analysts, the consensus estimate is that Evolution AB share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Evolution AB?
Analysts are divided on their view about Evolution AB share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evolution AB is a Sell and believe this share price will rise from its current level to --.
-
What Is Evolution AB's Price Target?
The price target for Evolution AB over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EVGGF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Evolution AB is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of EVGGF?
You can purchase shares of Evolution AB via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evolution AB shares.
-
What Is The Evolution AB Share Price Today?
Evolution AB was last trading at $69.25 per share. This represents the most recent stock quote for Evolution AB. Yesterday, Evolution AB closed at $87.48 per share.
-
How To Buy Evolution AB Stock Online?
In order to purchase Evolution AB stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
